ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

This article originally appeared here.
Share this content:
ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab
ASH: Lower Rate of Sickle Cell Pain Crises With Crizanlizumab

MONDAY, Dec. 5, 2016 (HealthDay News) -- High-dose crizanlizumab treatment is associated with a significantly lower rate of sickle cell-related pain crises than placebo, according to a study published online Dec. 3 in The New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 3 to 6 in San Diego.

Kenneth I. Ataga, M.B.B.S., from the University of North Carolina at Chapel Hill, and colleagues conducted a phase 2 trial involving patients with sickle cell disease who were randomized to receive low-dose crizanlizumab, high-dose crizanlizumab, or placebo administered intravenously over a period of 52 weeks. A total of 198 patients at 60 sites underwent randomization.

The researchers found that the median rate of crises per year was 1.63 and 2.98 for high-dose crizanlizumab versus placebo, respectively. The median time to the first crisis and to the second crisis was significantly longer with high-dose crizanlizumab therapy than placebo (4.07 versus 1.38 months and 10.32 versus 5.09 months). The median rate of uncomplicated crises per year was 1.08 and 2.91 for high-dose crizanlizumab versus placebo, respectively.

"In patients with sickle cell disease, crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises than placebo and was associated with a low incidence of adverse events," the authors write.

The study was funded by Selexys Pharmaceuticals.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »